New drug IRL757 passes first safety check in healthy humans

NCT ID NCT06493045

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety of a new drug, IRL757, in 82 healthy adults aged 18-55. Participants received either single or multiple doses of the drug or a placebo. The study focused on side effects and how the drug moves through the body, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IRL757

What this could lead to

If safe, this could pave the way for future studies to see if IRL757 might treat a disease.

What could go wrong

This is a very early, first-in-human trial in healthy people, not patients. It only checks safety, not whether the drug works for any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NOT DETERMINED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CTC Clinical Trial Consultants AB, Uppsala University Hospital

    Uppsala, Sweden